Since the 1980s, AR has been deeply studied as a drug target [8,9] because it transforms cytosolic glucose into sorbitol (a reaction that AKR1B10 and AKR1B15 cannot perform [7,10]), though only under hyperglycemia. The gene discussed is AR; the disease is Hyperglycemia.